Pfizer Announces Enrollment of First Patient in Phase 3 Trial in Sickle Cell Disease

By calovel On December 15, 2015 · Add Comment · In Pharmaceuticals, Pharmaceuticals - Featured Articles

RESET Trial to Assess Effectiveness and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Individuals with Sickle Cell Disease

Pfizer Inc. (NYSE:PFE) announced that the first patient has been enrolled in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study – a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease who are six years of age or older.

Read more here.

Indicators of an Emergency Situation

Patients and families should watch for the following conditions that need an urgent medical evaluation:
• Fever of 101° F or higher
• Chest pain
• Shortness of breath
• Increasing tiredness
• Abdominal swelling
• Unusual headache
• Any sudden weakness or loss of feeling
• Pain that will not go away with home treatment
• Priapism (painful erection that will not go down)
• Sudden vision change

Sickle Cell News from Around the Web
City Spotlights

Learn about sickle cell resources in: Atlanta, Georgia; Oakland, California

Pfizer Announces Enrollment of First Patient in Phase 3 Trial in Sickle Cell Disease

Indicators of an Emergency Situation

Sickle Cell News from Around the Web

City Spotlights

Notice

About this Site

Contact Us